NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of MediaAlpha, Inc. ("MediaAlpha" or the "Company") (NYSE:MAX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether MediaAlpha and certain of its officers and/or directors have […]
NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Icon Public Limited Company ("ICON" or the "Company") (NASDAQ:ICLR).��Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com�or 646-581-9980, ext.�7980. The investigation concerns whether ICON and certain of its officers and/or directors have engaged
NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ:NTLA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comâ?¯or 646-581-9980, ext.â?¯7980. The investigation concerns whether Intellia and certain of its officers and/or directors have engaged
NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ:REGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are
NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=124958&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or
NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Arvinas and certain of its officers and/or directors have
NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sonos, Inc. ("Sonos" or the "Company") (NASDAQ:SONO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Sonos and certain of its officers and/or directors have
NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ:AZN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether AstraZeneca and certain of its officers and/or directors have
NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Sun Communities, Inc. ("Sun Communities" or the "Company") (NYSE:SUI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are
NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Neurogene Inc. ("Neurogene" or the "Company") (NASDAQ:NGNE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Neurogene and certain of its officers and/or directors have